A later observational trial studying a new SGLT2i reported that henagliflozin might significantly improve the MoCA scores and plasma phosphorylated Tau protein among T2DM patients with MoCA lower than 26 [124]. This evidence concerns the gene MAPT and type 2 diabetes mellitus.